Eli Lilly

Category

Principal Investigator to COVID-19 Patients in Houston—Best Chance to Access Lilly’s Bamlanivimab Not Under EUA but via BLAZE-1 Study

Eli Lilly’s monoclonal antibody now known as bamlanivimab (formerly LY-CoV555) recently received an Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) to treat high risk COVID-19 patients. Recently, Houston Methodist physician and...

Lilly, NIAID & Care Access Research Transform How Studies Done to Reach Nursing Homes During COVID-19 Pandemic

On Aug. 3, TrialSite applauded the effort of  Lilly & Co. (NYSE: LLY) and the National Institute of Allergy and Infectious Diseases (NIAID) for the Blaze-2 clinical trial. Why? Because it’s one of the first, if not the first nationwide intervention during the...

Lilly on the Verge of COVID-19 Monoclonal Antibody EUA Approval First for High Risk Patients with Recent Mild-to-Moderate COVID-19 Diagnosis

TrialSite shared that Eli Lilly’s (Lilly) monoclonal antibody program targeting COVID-19 appeared to be working, at least according to some trial site reports. Now Lilly is moving to secure an emergency use authorization for its monotherapy (LY-CoV555) to the U.S....

Lilly’s Monoclonal Antibody Produces Positive Data, Company Gears up for Further Review & Inks Production Deal with Amgen

TrialSite News reported on Aug 22 that a South Texas trial site location reported growing confidence in a SARS-CoV-2 neutralizing antibody-based investigational product developed by Eli Lilly (Lilly) called LY-CoV555. Developed with the help of powerful discovery...

Eli Lilly’s BLAZE-1 Selects Aventiv Research in Columbus as Ohioans Investigate Advanced Monoclonal Antibodies Targeting COVID-19

TrialSite recently profiled Columbus, Ohio-based Aventiv Research as the independent trial site organization was selected by Pfizer as a site to participate in the BNT162 COVID-19 vaccine trial program. Now, local media (WSYX/WTTE) reports that the Columbus-based site...

Prominent New Orleans Physician Discusses Participation in Blaze-1 Study of World’s First Antibody Product Targeting COVID-19

Louisiana’s Ochsner Medical Center in Jefferson Parish is actively contributing its medical, scientific and research talents in the ongoing bid to combat the COVID-19 pandemic. Partnering with industry sponsors such as Eli Lilly, one the health provider’s prestigious...

Eli Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Eli Lilly and Company announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults...

Duke Clinical Research Institute Collaborates with BI & Eli Lilly to Lead EMPACT-MI Pragmatic Clinical Trial

Duke Clinical Research Institute (DCRI) inked a clinical trials collaborative deal with the world’s largest privately held drug company—Boehringer Ingelheim—and publicly traded Eli Lilly (NYSE:LLY) to launch the EMPACT-MI (EMPAgliflozin for the prevention of Chronic...

Pin It on Pinterest